Results 101 to 110 of about 20,711,708 (259)
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken +7 more
wiley +1 more source
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber +15 more
wiley +1 more source
Determination of Viability Summary Chrysler, LLC [PDF]
Determination of Viability Summar, Chrysler LLC -- Chrysler February 17 Plan: Viability ...
Chrysler Group, LLC.
core +1 more source
Abstract The anterior cruciate ligament (ACL) and anterolateral ligament (ALL) play key roles in maintaining rotational stability of the knee joint. Injuries that cause ACL tears have been shown to also frequently compromise the integrity of the ALL.
Taidhgin J. Keel +6 more
wiley +1 more source
Abstract Surgical repair remains the standard of care for complete patellar tendon ruptures. However, healing is often challenging due to the tendon's poor biological environment and high tensile stress at the repair site. Bioinductive implants have been introduced to enhance tendon healing; however, they often lack early structural reinforcement. This
McKenzie A. Mayer +4 more
wiley +1 more source
Introduction This analysis used pharmacokinetic (PK) modeling to characterize dosing conversions and switching strategies from R064766, a once-every-2-weeks, intramuscular long-acting injectable antipsychotic (LAI) formulation of risperidone microspheres,
Itay Perlstein +10 more
doaj +1 more source
Aims The Black Triangle Scheme, introduced in 2018 in Australia, does not appear to have increased the quantity of adverse drug event (ADE) reports. This study evaluated healthcare professionals' (HCPs') and consumers' awareness of the scheme, its influence on intentions for future ADE reporting, and suggested improvements.
Eyob Alemayehu Gebreyohannes +7 more
wiley +1 more source
Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Nele Goeyvaerts +6 more
wiley +1 more source
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source
Twenty years of inhaler therapy: A nationwide drug utilization study
Aims This study aimed to map nationwide trends and prescribing patterns in inhaler use from 2004 to 2023. In light of evolving clinical guidelines and attention to the environmental impact of inhalers within recent years, we also examined variation in prescribing behaviour and patient‐level treatment choices. Methods Using nationwide health registries,
Katrine Bitsch Johansen +5 more
wiley +1 more source

